Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2017

View Archived Issues

CFFT award supports Aridis' development of Panaecin for patients with cystic fibrosis

AMAG Pharmaceuticals enters licensing agreement with Palatin Technologies for bremelanotide

Aduro Biotech, Merck & Co. to investigate CRS-207 plus pembrolizumab in gastric cancer

ProNAi Therapeutics changes name to Sierra Oncology, transfers phase I trials of SRA-737

Phase I trial begins for Moderna's mRNA-based Zika vaccine candidate

DSMB recommends continuation of Evgen's phase II trial of SFX-01 in subarachnoid hemorrhage

IACTA acquires North American rights to Nanomerics' NM-133 for dry eye

Gemcabene shows efficacy for NASH in preclinical proof-of-concept study

LegoChem and Takeda enter research licensing agreement to evaluate next-generation ADC candidates

Abivax to receive funding to strengthen antiviral platform

G1 Therapeutics begins three breast cancer drug programs

Gilead's Vemlidy approved for HBV infection in E.U.

FDA grants orphan drug status to Sangamo Therapeutics' SB-318

Targeted knockdown of SMN-AS1 as a potential new SMA therapeutic strategy

FDA issues complete response letter for Tesaro's NDA for intravenous rolapitant

Genomics-based drug repurposing identifies sitagliptin as potential antiepileptic drug

FDA grants QIDP and fast track designations to VivaGel in bacterial vaginosis

RedHill Biopharma's RHB-104 awarded FDA QIDP designation

Gas6-AXL pathway as a new target for development of ZIKV therapies

Bird Rock Bio cleared to begin phase I study of namacizumab

Bayer patents anticancer compounds

Takeda reports M1 PAMs for Alzheimer's disease

Kissei Pharmaceutical describes TRPM8 antagonists

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...